Decision

Apotex Inc. v. Sanofi-Aventis, 2010 FC 182 (Clopidogrel*)

Proth. Tabib - 2010-02-18

Read full decision. Automatically generated summary:

Apotex Inc. started action T-644-09 in May 2009, seeking a declaration that the product it intends to manufacture and sell in Canada, made with clopidogrel bisulfate and/or clopidogrel besylate, will not infringe Sanofi-Aventis’ Canadian Patent ‘777, and seeking a declaration that the said patent is invalid. One month later, Sanofi-Aventis and Bristol-Myers Squibb Sanofi Pharmaceutical Holdings Partnership (jointly “Sanofi”) sued Apotex Inc. and Apotex Pharmachem Inc. (jointly “Apotex”) alleging that Apotex is already manufacturing and exporting for sale in various countries a clopidogrel bisulfate product, infringing the ’777 patent. Both parties requested that early trial dates be set. The actions were consolidated and trial dates have been set aside for the trial to begin in April 2011.

Decision relates to:

  • T-644-09 - APOTEX INC. v. SANOFI-AVENTIS ET AL
  • T-933-09 - SANOFI-AVENTIS AND OTHER v. APOTEX INC. AND OTHERS

 

Canadian Intellectual Property